| ISP (N = 193) | No ISP (N = 67) | Healthy controls (N = 46) |
---|---|---|---|
Age | |||
 Years, mean (SD) | 43.8 (14.2) | 46.2 (13.4) | 45.6 (13.0) |
Sex, No (%) | |||
 Female | 120 (62.2) | 44 (65.7) | 28 (60.9) |
 Male | 73 (37.8) | 23 (34.3) | 18 (39.1) |
BMI | |||
 Mean (SD) | 25.6 (4.6) | 25.1 (4.4) | 24.4 (3.4) |
IMID diagnosis, No (%) | |||
 Rheumatic disease | |||
  Rheumatoid arthritis | 25 (13.0) | 0 (0) | NA |
  SLE | 16 (8.3) | 4 (6.0) | NA |
  Spondylarthritis | 11 (5.7) | 2 (3.0) | NA |
  Other rheumatic disease | 4 (2.0) | 1 (1.5) | NA |
 Gastrointestinal disease | |||
  Crohn's disease | 32 (16.6) | 11 (16.4) | NA |
  Ulcerating colitis | 19 (9.8) | 3 (4.5) | NA |
  Other IBD | 3 (1.6) | 1 (1.5) | NA |
 Neurological disease | |||
  MS and NMO | 31 (16.1) | 17 (25.4) | NA |
  Inflammatory neuropathies and myopathies | 12 (6.2) | 0 (0) | NA |
  Myasthenia gravis | 11 (5.7) | 3 (4.5) | NA |
 Dermatological disease | |||
  Atopic dermatitis | 12 (6.2) | 0 (0) | - |
  Other dermatological | 17 (8.8) | 23 (34.3) | NA |
 Other IMID | |||
  Other | 0 (0) | 2 (3.0) | NA |
Medication group, No (%) | |||
 Anti-CD20 | 14 (7.3) | 0 (0) | 0 (0) |
 Anti-TNF | 49 (25.4) | 0 (0) | 0 (0) |
 Other ISP | 130 (67.4) | 0 (0) | 0 (0) |
SARS-CoV-2 infection diagnosis, No (%) | |||
 PCR test positive | 189 (97.9) | 63 (94.0) | 44 (95.7) |
 Antigen test positive | 4 (2.1) | 4 (6.0) | 2 (4.4) |
COVID-19 severity, No (%)a | |||
 Asymptomatic | 12 (6.2) | 2 (3.0) | 0 (0) |
 Mild | 171 (88.6) | 63 (94.0) | 45 (100) |
 Moderate (hospitalization with oxygen) | 5 (2.6) | 1 (1.5) | 0 (0) |
 Moderate (hospitalization without oxygen) | 4 (2.1) | 0 (0) | 0 (0) |
 Severe (ICU admission) | 1 (0.5) | 1 (1.5) | 0 (0) |
 Death | 0 (0) | 0 (0) | 0 (0) |
Time from infection to sample | |||
 Days, median [IQR] | 165 [96.3–224] | 199 [90.5–233] | 189 [85.5–230] |